Myriad Genetics Inc.
) presented clinical data from a study on the myRisk Hereditary
Cancer test at the 2013 San Antonio Breast Cancer Symposium. The
study was planned as part of a phased launch for myRisk
Hereditary Cancer test.
myRisk is a novel diagnostic test that uses next-generation
sequencing technology to evaluate 25 genes associated with eight
major hereditary cancers including breast, colorectal, ovarian,
endometrial, pancreatic, prostate, gastric and melanoma.
The clinical data demonstrates the superiority of this diagnostic
test over other testing modes. It was found that myRisk has the
ability to identify 51% more patients with higher risk of
hereditary breast and ovarian cancer than testing of BRCA1 and
BRCA2 genes alone.
The study measured mutations in 25 cancer-causing genes among
patients who were referred for BRCA1/2 testing. Amongst 1,951
patients, 275 patients tested positive for the harmful mutation
with the myRisk test whereas testing with BRCA1 and BRCA2 genes
detected only 182 of the mutation carriers.
This implies a straight 51% increase in hereditary breast and
ovarian cancer mutation detection using the myRisk test.
Furthermore, in this study, myRisk test delivered a remarkable
accuracy of 99.99%.
ACTELION LTD (ALIOF): Get Free Report
HESKA CORP (HSKA): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis
VANDA PHARMACT (VNDA): Free Stock Analysis
To read this article on Zacks.com click here.
The study results come close on the heels of the recently
presented data on the myRisk test at the Collaborative Group of
the Americas on Inherited Colorectal Cancer (CGA) Annual Meeting.
Myriad had reported a 61% improvement in detection of hereditary
colon cancer and 99.9% accuracy with the myRisk test.
Such positive results come as a breather for Myriad, as it is
currently going through a difficult time. The company has been
sued by Invitae Corporation in response to a previous lawsuit
filed by Myriad, regarding Invitae's BRCA and MUTYH genetic
tests. Invitae has dismissed the allegations of infringement.
Moreover, the recent proposal from the Centers for Medicare &
Medicaid Services (CMS) to cut down on the payment of
BRACAnalysis greatly affected the share prices of the company.
Myriad is banking on these encouraging study results to help it
get back into form and garner greater market share on the back of
this revolutionary cancer detection test.
Currently, Myriad Genetics carries a Zacks Rank #2 (Buy).
Investors interested in the industry may also consider stocks
Vanda Pharmaceuticals, Inc
). All these stocks sport a Zacks Rank #1 (Strong Buy).